0000000000044568

AUTHOR

Donatella Ferraro

showing 91 related works from this author

Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induct…

2002

High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic hepatitis C were randomised to receive, after 4 weeks of 10 mU daily of alpha-interferon (induction), 3 mU daily for 22 weeks and 3 mU thrice weekly for 26 weeks of either interferon alone (monotherapy) or interferon plus 1000-1200 mg daily of ribavirin (combination therapy). At the end of the induction phase, 23 (56%) subjects had cleared HCV-RNA. During therapy, breakthrough w…

AdultMaleCombination therapyAdolescentHepacivirusAlpha interferonViremiaEnzyme-Linked Immunosorbent AssayHepacivirusPharmacologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialInterferonlawVirologyRibavirinHumansMedicineViremiaAgedAntiviral AgentHepatologybiologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseInfectious DiseasesTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessmedicine.drugHuman
researchProduct

No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.

2013

OBJECTIVES: The widespread use of tumour necrosis factor (TNF)-targeted therapies in patients with rheumatic, digestive and dermatologic diseases has been associated with reports of reactivation of HBV replication and ensuing hepatitis flares both in asymptomatic HBsAg carriers and in subjects with occult HBV infection. The aim of our work was to investigate in a two-year prospective study the potential for HBV reactivation in patients with inflammatory joint diseases undergoing anti-TNF treatment from a southern Mediterranean area. METHODS: Fifty-seven consecutive outpatients attending the Academic Unit of Rheumatology at the University of Palermo (12 with rheumatoid arthritis, 17 with pso…

AdultMaleHepatitis B virusTime Factorsoccult HBV-DNAAntiviral AgentsPolymerase Chain ReactionRisk AssessmentRisk FactorsRheumatic Diseasesoccult HBV-DNA rheumatic diseases anti-TNFHumansProspective Studiesrheumatic diseaseAcademic Medical CentersHepatitis B Surface AntigensTumor Necrosis Factor-alphavirus diseasesanti-TNFMiddle AgedHepatitis Bdigestive system diseasesTreatment OutcomeItalyLamivudineAntirheumatic AgentsDNA ViralFemaleVirus ActivationBiomarkers
researchProduct

HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy

2005

In hepatitis B virus (HBV) cirrhosis patients on long-term lamivudine (LAM), the relationships between HBV suppression, development of viral resistance and disease outcome are unclear. We analysed the dynamic of serum HBV-DNA and its relationship with the clinical course of 59 patients (52 males, mean age 51.4 ±8.4 years, 12 HBeAg positive and 47 HBeAg negative, and 57 genotype D and two genotype A) with cirrhosis (45 in Child-Turcotte-Pugh class A) and high levels of serum HBV-DNA (median 14.7x107 genomes/ml) treated with LAM [median (range): 44 (15–78) months]. A total of 50 patients (84.7%) achieved a virological response (serum HBV-DNA negative by PCR) during the first 6 months of ther…

AdultLiver CirrhosisMaleHepatitis B virusCirrhosisHBV DNA Lamivudine Therapy suppression HBV diseasemedicine.disease_causeVirus ReplicationAntiviral AgentsVirusDrug Administration ScheduleDisease courseCohort StudiesOrthohepadnavirusmedicineHumansPharmacology (medical)AgedPharmacologyHepatitis B virusbiologyReverse-transcriptase inhibitorLamivudineMiddle Agedbiology.organism_classificationmedicine.diseaseHepatitis BVirologydigestive system diseasesInfectious DiseasesHepadnaviridaeLamivudineDNA ViralMutationFemalemedicine.drug
researchProduct

Point‐of‐care HCV RNA testing in the setting of DAA therapy: HCV‐FiS (HEpatitis C Virus Fingerstick Study)

2019

HCV-RNA assessment during therapy with Direct-Acting Antiviral (DAA) regimens still relies on assays requiring blood collection and transport to a specialised laboratory, which may compromise linkage to care. GeneXpert-HCV Viral Load (GXHVL) (Cepheid) is a plasma-based assay used at point of care (POC) with a sensitivity of ≤10 IU/mL, and, results available within 2 hours. Fifty-nine consecutive HCV-patients ready for DAAs treatment were enrolled. HCV-RNA was simultaneously tested using Roche TaqMan RT-PCR (venous blood sample) and GXHVL (capillary blood collected by fingerstick), at baseline (BL), week 4 (W4) of therapy, end of therapy (EOT) and week 12 of follow-up (W12FU). Both assays de…

Malemedicine.medical_specialtyEnd of therapyFingerstickHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsInternal medicineTaqManmedicineOutpatient settingHumansHCV DAAAgedPoint of careHepatologybusiness.industryVenous blood sampleMiddle AgedViral LoadHepatitis CPoint-of-Care TestingRNA ViralFemalebusinessViral loadLiver International
researchProduct

An Outbreak of Hepatitis C Virus Infection Among Transfused Thalassemia Patients: Root Cause Analysis, Phylogenetic Epidemiology and Antiviral Therapy

2021

Background: Occurrence of HCV infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings. We report an outbreak of 11 patients with HCV acute hepatitis (seven new infections and four re-infections) among 128 thalassemia patients followed at a Hospital in Sicily. Methods All patients with acute hepatitis and known chronic infection were tested for HCV-RNA, HCV genotyping, and NS3, NS5A and NS5B HCV-genomic regions sequencing.  To identify transmission clusters we built phylogenetic trees for each gene employing Bayesian methods.  Findings All patients with acute hepatitis were infected with HCV genotype 1b…

Ledipasvirmedicine.medical_specialtyBlood transfusionSofosbuvirTransmission (medicine)business.industryHepatitis C virusmedicine.medical_treatmentmedicine.disease_causeHelsinki declarationchemistry.chemical_compoundChronic infectionchemistryInternal medicineEpidemiologymedicinebusinessmedicine.drugSSRN Electronic Journal
researchProduct

Binding of flunitrazepam to differentiating neurons cultured in a chemically defined, hormone-supplemented medium

1990

[3H]Flunitrazepam (FNZ) binding to cortical neurons from fetal rat brain was investigated in vitro. The use of a synthetic medium specific for neurons made it possible to plot a developmental curve of3H-FNZ binding in an almost pure neuronal culture. Detectable specific binding was present in vitro at time 0 (that is, the 16th gestational day). A progressive increase of binding, due to an increment in the number of recognition sites, was observed on the subsequent days. The affinity of the specific binding sites to3H-FNZ was enhanced by the addition of exogenous GABA, whereas the density was not affected. © 1990 Plenum Publishing Corporation.

Central nervous systemFlunitrazepamBiologySettore BIO/19 - Microbiologia GeneraleBiochemistrygamma-Aminobutyric acidGABACellular and Molecular NeurosciencemedicineAnimalsBinding siteCells Culturedgamma-Aminobutyric AcidNeuronsFetusCell DifferentiationGeneral MedicineHormonesIn vitroCulture MediaCell biologymedicine.anatomical_structureneuronal cultureCell cultureCerebral cortexSettore MED/26 - NeurologiaFlunitrazepamNeurosciencemedicine.drugNeurochemical Research
researchProduct

Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.

2008

Iron overload and hepatitis virus C infection cause liver fibrosis in thalassemics. In a monocentric retrospective analysis of liver disease in a cohort of 191 transfusion-dependent thalassemics, in 126 patients who had undergone liver biopsy (mean age 17.2 years; 58 hepatitis virus C-RNA positive and 68 hepatitis virus C-RNA negative) the liver iron concentration (median 2.4 mg/gr dry liver weight) was closely related to serum ferritin levels (R = 0.58; p<0.0001). Male gender (OR 4.12) and serum hepatitis virus C-RNA positivity (OR 11.04) were independent risk factors for advanced liver fibrosis. The majority of hepatitis virus C-RNA negative patients with low iron load did not develop liv…

AdultLiver CirrhosisMaleLiver Iron ConcentrationCirrhosisIron OverloadAdolescentHepatitis C virusBiopsyHepacivirusSettore MED/08 - Anatomia Patologicamedicine.disease_causeCohort StudiesLiver diseasethalassemic iron chronic hepatitis CMedicineHumansRetrospective StudiesSettore MED/12 - Gastroenterologiamedicine.diagnostic_testbusiness.industryTransfusion ReactionHematologyHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseLiverLiver biopsyImmunologySplenectomyThalassemiaFemalebusinessHepatic fibrosisViral loadHaematologica
researchProduct

Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance.

2013

Background: Reversibility of advanced fibrosis after HCV-clearance is an important goal of therapy. Objectives: Measuring liver stiffness (LS) by transient elastography (TE) might be helpful in this setting. Patients and Methods: We evaluated 104 patients with biopsy-proven chronic hepatitis C (CHC) and sustained virological response (SVR) after Peg-Interferon (IFN) plus ribavirin since at least 18 months. HCV-eradication was confirmed searching for serum HCV-RNA (TMA® sensitivity > 5-10 IU/ml). Data from literature reported the best LS cut-off values for different stages of liver fibrosis were 7.1 kPa for Metavir stage 2 (F2), 9.5 kPa for F3 and 12.5 for cirrhosis (F4). Results: TE was not…

Liver Cirrhosismedicine.medical_specialtyPathologyCirrhosisGastroenterologychemistry.chemical_compoundFibrosisInternal medicineBiopsyMedicineStage (cooking)Hepatologymedicine.diagnostic_testbusiness.industryRibavirinmedicine.diseaseKowsarliver stiffnessInfectious DiseaseschemistryElasticity Imaging TechniquesSteatosisInsulin ResistancebusinessTransient elastographyResearch ArticleHepatitis monthly
researchProduct

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomi…

2006

AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in retreating chronic hepatitis C patients who relapsed after recombinant interferon (rIFN) monotherapy. METHODS: Forty-five patients (34 males and 11 females) with chronic hepatitis due to hepatitis C virus (HCV) genotype 1 who relapsed after a previous course of rIFN monotherapy were randomized to receive 9 μg CIFN three times per week for 52 wk (group A, n = 22) or 18 μg CIFN three times per week for 52 wk (group B, n = 23) in combination with ribavirin 800 to 1200 mg daily for 52 wk (according to body weight). Virological response was evaluated at week 24 (EVR), at the end of treatment (ETR)…

AdultMalemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicavirusesHepacivirusAlpha interferonHepacivirusPharmacologyGastroenterologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInterferonRecurrenceInternal medicineRibavirinmedicineHumansIn patientSettore MED/12 - GastroenterologiabiologyDose-Response Relationship Drugbusiness.industryRibavirinGastroenterologyInterferon-alphaGeneral MedicineHepatitis C ChronicMiddle AgedViral Loadbiology.organism_classificationhumanitiesRecombinant ProteinsTreatment OutcomechemistryInterferon Type IInterferon Ribavirin Hepatitis C virus Hepatitis C RelapserDrug Therapy CombinationFemalebusinessViral loadInterferon type IRapid Communicationmedicine.drugWorld journal of gastroenterology
researchProduct

HCV CLEARANCE AFTER PEG IFN PLUS RBV IMPROVES THE COURSE OF HCV CIRRHOSIS REGARDLESS OF PORTAL HYPERTENSION

2009

medicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/12 - GastroenterologiaCirrhosisHepatologybusiness.industryPEG IFN/RBV HCV CIRRHOSISGastroenterologyHcv clearancemedicine.diseaseGastroenterologyInternal medicinemedicinePortal hypertensionbusiness
researchProduct

Endemic hepatitis C virus infection in a Sicilian town: Further evidence for iatrogenic transmission

2002

The prevalence of and risk factors for HCV and HBV infections in the general population and the predictive value of ALT screening in identifying anti-HCV positive subjects have been evaluated in a small Sicilian town. A random 1:4 sampling from the census of the general population was performed. Anti-HCV, HCV-RNA, HCV genotype, HBsAg, and anti-HBc were tested. The linkage between HCV infection and potential risk factors was evaluated by multiple logistic regression analysis. Among 721 subjects studied, 75 (10.4%) were anti-HCV positive. The HCV infection rate increased from 0.4% in subjects 10–29 years of age to 34% in those > 60 years of age. Among the 75 anti-HCV positive subjects, 66.7% …

Hepatitis B virusHBsAgeducation.field_of_studybusiness.industryIncidence (epidemiology)Populationvirus diseasesHepatitis CHepatitis Bmedicine.diseasemedicine.disease_causeVirologydigestive system diseasesInfectious DiseasesVirologyPredictive value of testsmedicineViral diseaseeducationbusinessJournal of Medical Virology
researchProduct

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals

2017

Anecdotal reports suggest that patients with chronic hepatitis C virus (HCV) hepatitis and overt or occult hepatitis B virus (HBV) coinfection may reactivate HBV when HCV is suppressed or cleared by direct-acting antivirals (DAAs). We assessed the prevalence of overt or previous HBV coinfection and the risk of HBV reactivation in patients with HCV cirrhosis treated with DAAs. This was a retrospective cohort of 104 consecutive patients with HCV cirrhosis treated with DAAs. Serum HCV-RNA and HBV-DNA were tested at weeks 4, 8 and 12 of DAAs therapy and at week 12 of follow-up. At the start of DAAs, eight patients (7.7%) were HBsAg positive/HBeAg negative with undetectable HBV-DNA and low level…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCirrhosisHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsVirus03 medical and health sciencesHepatitis B Chronic0302 clinical medicineVirologymedicineHumansHBV-DNA reactivationnucleos(t)ide analogues therapyAgedRetrospective StudiesHepatitisHepatitis B virusHepatologybiologyCoinfectionbusiness.industryvirus diseasesRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationVirologyprevious HBV infectiondigestive system diseasesInfectious DiseasesHBV/HCV coinfection030220 oncology & carcinogenesisDNA ViralCoinfectionRNA ViralFemaleVirus Activation030211 gastroenterology & hepatologysustained virological responsebusiness
researchProduct

Evaluation of the diagnostic performances of two commercially available assays for the detection of enteric adenovirus antigens

2021

The performance of 2 antigenic commercial assays for enteric adenovirus (AdV) infection, bioNexia Rota-Adeno ImmunoChromatographic Tests (ICT) and LIAISON® Adenovirus ChemiLuminescence Immuno Assays (CLIA), was evaluated on 321 stools from children hospitalized for acute gastroenteritis in Palermo, Italy, using a Real time-PCR (Rt-PCR) as reference method. The CLIA showed higher sensitivity (77% vs 60%), accuracy (94.4 vs 90.9) and concordance (k: 0.81 vs 0.67) with respect to ICT, despite equivalent specificity (98.8%). Using the Ct values of the Rt-PCR as a proxy of the fecal viral load, similar Ct values (mean 9.32 vs 9.89) were observed among the true positive samples, whilst a signific…

Microbiology (medical)medicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaAdolescentAdenoviridae InfectionsConcordanceSensitivity and SpecificityGastroenterologyAdenoviridaeFecesAntigenChemiluminescent immunoassayInternal medicineFecal antigens detectionmedicineHumansChemiluminescent immunoassayChildAntigens ViralFecesImmuno chromatographyAcute gastroenteritibusiness.industrySignificant differenceInfant NewbornEnteric adenoviruseInfantGeneral MedicineAcute gastroenteritisGastroenteritisHospitalizationInfectious DiseasesItalyChild PreschoolLuminescent MeasurementsReagent Kits DiagnosticDiagnostic performancebusinessViral load
researchProduct

150 LIVER RELATED EVENTS AND SURVIVAL IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS: THE ROLE OF SUSTAINED VIROLOGICAL RESPONSE TO PEG-IFN BASED THERAPY…

2011

Virological responsemedicine.medical_specialtyCirrhosisHepatologybusiness.industryInternal medicinemedicinePortal hypertensionIn patientmedicine.diseasebusinessGastroenterologyJournal of Hepatology
researchProduct

Rat CNS cell culture. Enhancement of neuronal survival and delay of glial proliferation by serum from patients with multiple sclerosis. A morphologic…

1984

The addition of serum from multiple sclerosis (MS) patients to the culture medium of dissociated cells from cerebral hemispheres of rat embryos caused a delay in glial proliferation and an enhancement of neuronal survival. Sera from normal individuals and patients with other neurological diseases failed to show this effect. These morphological observations are interpreted as the outcome of inhibition of in vitro gliogenesis.

Central Nervous Systemmedicine.medical_specialtyPathologyNeurologyMultiple SclerosisDermatologyBiologyGliotoxinmedicineAnimalsCells CulturedGliogenesisNeuronsGeneral NeuroscienceMultiple sclerosisEmbryoCell DifferentiationGeneral MedicineMycotoxinsmedicine.diseaseEmbryo MammalianIn vitroRatsPsychiatry and Mental healthCell cultureOrgan SpecificityImmunologyNeurology (clinical)NeurogliaItalian journal of neurological sciences
researchProduct

Inhibition of glial proliferation in vitro by serum from patients with multiple sclerosis

1987

Primary cell cultures from fetal rat CNS have been employed to evaluate the effects caused by the addition of serum from patients affected by multiple sclerosis (MS). MS-serum supplemented media caused a decrease in [3H]-thymidine incorporation into the cultures, thus indicating an inhibitory effect on proliferating glial cells. Sera from patients in remission stage of the disease showed an inhibitory effect not significatively lower than those from patients in acute stage. These results suggest that glial cells may be a target of circulating factors present in MS.

AdultMalemedicine.medical_specialtyPathologyMultiple SclerosisDiseaseBiologyTritiumSettore BIO/19 - Microbiologia GeneraleInternal medicineSettore BIO/10 - BiochimicamedicineAnimalsHumansCells CulturedFetusNeuroscience (all)Cell growthMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseaseIn vitroAcute stageRatsEndocrinologymedicine.anatomical_structureNeurologyCell cultureNeurogliaFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurogliaCell DivisionThymidine
researchProduct

VALUTAZIONE DELLA CLEARANCE DI HCV-RNA SOTTO TRATTAMENTO ANTIVIRALE CON TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA)

2005

-

lcsh:QR1-502General Medicinelcsh:MicrobiologyMicrobiologia Medica
researchProduct

Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination.

2022

In order to determine the humoral protective response against SARS-CoV-2, the vaccine-induced and naturally induced neutralizing antibodies (NtAbs) responses against SARS-CoV-2 variants circulating in Italy through in vitro live virus neutralization assay were evaluated. A total of 39 SARS-CoV-2 recovered subjects (COVID-19+) and 63 subjects with a two-dose cycle of the BNT16262 vaccine were enrolled. A single serum sample was tested for COVID-19+ at 35–52 days post-positive swab, while vaccinees blood samples were taken at one (V1) and at three months (V3) after administration of the second vaccine dose. Significantly higher NtAb titers were found against B.1 and Alpha in both COVID-19+ an…

SARS-CoV-2; VOC; Omicron; Italy; neutralizing antibody titers; NtAbPharmacologyInfectious DiseasesItalySARS-CoV-2OmicronVOCDrug DiscoveryImmunologyneutralizing antibody titerNtAbPharmacology (medical)Vaccines
researchProduct

Characterization of measles virus strains circulating in Southern Italy (Palermo area, Sicily) between 2010 and 2011

2015

Measles virus (MV) was classified in 24 genotypes that show a distinct geographic distribution. Genotypes contain multiple distinct lineages. In 2011 large outbreaks of measles occurred in Italy and in many European countries. Aims of this study are to analyze the intra-genotype variability and to follow the importation and the spread of new MV strains in Sicily. A fragment of 450. bps of MV C-terminal nucleoprotein was sequenced from sera of 73 Sicilian patients with symptomatic measles infections, occurred between 2010 and 2011. Five MV strains were D4 genotype and 68 were D8 genotype. The MV/D4 sequences were related to MV/D4-Enfield variant. Two lineages of MV/D8 genotypes, related to M…

AdultMale0301 basic medicineMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaAdolescentGenotypeSequence analysis030106 microbiologyHistory 21st CenturyMicrobiologyMeaslesMeasles virusYoung Adult03 medical and health sciencesGeneticMeasleGenotypeGenetic variationGeneticsmedicineHumansSicilyMolecular BiologyMeasles virus intra-genotypes variabilityPhylogenyEcology Evolution Behavior and SystematicsbiologyMeasles eliminationGenetic VariationOutbreakSequence Analysis DNAbiology.organism_classificationmedicine.diseaseEcology Evolution Behavior and SystematicVirologylanguage.human_languageGeographic distributionInfectious DiseasesMeasles virusMeasles virus genotypeMeasles virulanguageRNA ViralFemaleSicilianMeasles virus lineageMeaslesHumanInfection, Genetics and Evolution
researchProduct

Triiodothyronine-Induced Shortening of Chromatin Repeat Length in Neurons Cultured in a Chemically Denned Medium

1987

Abstract: At the time of terminal differentiation, mammalian cortical neurons undergo a dramatic change in the structural organization of their chromatin: the nucleosomal repeat length shortens from ∼200 base pairs in fetuses to a value of 165 base pairs after birth. These events occur several days after the end of neuronal proliferation. Previously, we reported that rat cortical neurons cultured in a very selective synthetic medium were not yet programmed to these events at the end of mitotic cycles. Herein, we report that addition of triiodothyronine to neuronal cultures induces a shortening of the chromatin repeat length comparable to the natural one. Copyright © 1987, Wiley Blackwell. A…

Neuronal terminal differentiationTime FactorsCellular differentiationBiologySettore BIO/19 - Microbiologia GeneraleChromatin structureBiochemistryCellular and Molecular NeuroscienceSettore BIO/10 - BiochimicamedicineAnimalsNucleosomeMitosisCells CulturedCerebral CortexNeuronsGeneticsNucleosomal Repeat LengthTriiodothyronineDNAChromatinCulture MediaRatsChromatinCell biologyChemically denned medium)Chemically defined mediummedicine.anatomical_structurenervous systemTriiodothyronineSettore MED/26 - NeurologiaNeuronJournal of Neurochemistry
researchProduct

Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B…

2009

Background The high degree of diversity of the hepatitis B virus (HBV) quasispecies in chronically infected individuals raises the possibility that HBV genetic variants favouring resistance to nucleoside/nucleotide analogues (NAs) might pre-exist to treatment. The aim of this study was to investigate the genetic variability of the entire HBV reverse transcriptase (RT) domain and of the overlapping S gene in a large series of untreated hepatitis B surface antigen carriers and in lamivudine (3TC)-resistant patients. Methods Sequencing analysis of the entire HBV RT domain of isolates from 100 untreated (treatment- naive group) and 59 3TC-resistant (3TC-resistant group) consecutive patients wit…

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaHepatitis B virusAdult; Aged; Drug Resistance; Viral; Female; Genetic Variation; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B; Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Reverse Transcriptase Inhibitors; Sequence Analysis; DNA; Treatment OutcomeDrug ResistanceViral quasispeciesmedicine.disease_causeVirusHepatitis B ChronicOrthohepadnavirusDrug Resistance ViralmedicineHumansPharmacology (medical)ViralChronicAgedPharmacologyHepatitis B virusSettore MED/12 - GastroenterologiaHepatitis B Surface AntigensbiologyReverse-transcriptase inhibitorLamivudineGenetic VariationRNA-Directed DNA PolymeraseSequence Analysis DNADNAMiddle Agedbiology.organism_classificationHepatitis BVirologyReverse transcriptaseInfectious DiseasesTreatment OutcomeHepadnaviridaeLamivudineMutationReverse Transcriptase InhibitorsHBV reverse transcriptase gene S lamivudine resistantFemaleSequence Analysismedicine.drug
researchProduct

RUOLO DELL’INFEZIONE OCCULTA DA HBV NEL PAZIENTE IMMUNOCOMPROMESSO

2005

-

lcsh:QR1-502lcsh:MicrobiologyMicrobiologia Medica
researchProduct

Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months

2000

Abstract Background/Aims: Retreatment of relapses of chronic hepatitis C with a standard regimen of interferon plus ribavirin for 6 months obtains a sustained response in a minority of patients with high viraemia and genotype 1b . We aimed to assess whether increasing the interferon dose and prolonging the time of combined treatment may enhance the effectiveness, and also to evaluate the tolerability, and to identify the determinants of sustained response. Methods: Fifty subjects with chronic hepatitis C who had relapsed after one or more courses of α-interferon monotherapy were randomised to receive α 2 b interferon (6 MU tiw) plus ribavirin (1000–1200 mg daily) for 6 or 12 months. ALT nor…

AdultMalemedicine.medical_specialtyGenotypemedicine.medical_treatmentAlpha interferonHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyDrug Administration Schedulechemistry.chemical_compoundRecurrenceInterferonInternal medicineRibavirinmedicineHumansInterferon alfaChemotherapyDose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C ChronicMiddle AgedRecombinant ProteinsAnti-Bacterial AgentsSurgeryRegimenTreatment OutcomechemistryTolerabilityRNA ViralDrug Therapy CombinationFemaleComplicationbusinessmedicine.drugJournal of Hepatology
researchProduct

Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis

2002

Abstract Background. Patients with chronic hepatitis C infected by hepatitis A virus have a substantial risk of fulminant hepatitis or death, while the course of hepatitis A virus is uncomplicated in most subjects with chronic hepatitis B. Aim. To evaluate the prevalence of anti-hepatitis A virus antibodies and the incidence of hepatitis A virus seroconversion in a nationwide sample of 530 patients with chronic hepatitis B and/or hepatitis C infection initially susceptible to this infection after a follow-up of some years. Results. The overall anti-hepatitis A virus prevalence was 85.7%, with no difference between males and females. By the age of 50 years, almost all patients were found to …

AdultMalemedicine.medical_specialtyAdolescentHepatitis C virusmedicine.disease_causeHepatitis A AntibodiesVirusHepatitis B ChronicSeroepidemiologic StudiesInternal medicinemedicineHumansSeroconversionFulminant hepatitisAgedHepatitis B virusHepatologybusiness.industryIncidenceGastroenterologyHepatitis CHepatitis BHepatitis AHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyChronic liver disease; Hepatitis A virus superinfection; Hepatitis B virus; Hepatitis C virus;ItalyHepatitis A AntibodieFemalebusinessViral hepatitisHepatitis A Virus HumanHuman
researchProduct

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

2004

Abstract Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for haematological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 on lymphoid cells, produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed a full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab. Lam…

HepatitisHepatitis B virusHBsAgmedicine.diagnostic_testCD52business.industryImmunologyvirus diseasesLamivudineCell BiologyHematologyHepatitis Bmedicine.diseasemedicine.disease_causeBiochemistrydigestive system diseasesLiver biopsyImmunologymedicineAlemtuzumabbusinessmedicine.drugBlood
researchProduct

Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?

2002

Abstract Background . Hepatitis G virus can cause chronic infection in man but the role of this agent in chronic liver disease is poorly understood. Little is known about the relation of another newly discovered agent, the TT virus, with chronic liver disease. Aim . To investigate the rate of infection with hepatitis G virus and TT virus in patients with cryptogenic chronic liver disease. Patients . A total of 23 subjects with chronically raised alanine transaminase and a liver biopsy in whom all known causes of liver disease had been excluded, and 4D subjects with hepatitis C virus-related chronic liver disease. Methods . Evaluation of anti-hepatitis G virus by enzyme immunoassay. Hepatiti…

AdultMaleCirrhosisHepatitis Viral HumanvirusesHepatitis C virusGB virus Cmedicine.disease_causeChronic liver diseaseLiver diseasemedicineHumansHepatitis ChronicTorque teno virusHepatitis B virusHepatitisHepatologymedicine.diagnostic_testReverse Transcriptase Polymerase Chain Reactionbusiness.industryGastroenterologyAlanine TransaminaseHepatitis CFlaviviridae InfectionsMiddle Agedmedicine.diseaseVirologyDNA Virus InfectionsLiverLiver biopsyFemalebusinessDigestive and Liver Disease
researchProduct

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial

2007

Abstract BACKGROUND/AIMS: Risks and benefits of antiviral therapy in HCV cirrhosis with portal hypertension are poorly known. METHODS: We performed a randomized controlled trial in 102 HCV patients with compensated cirrhosis and portal hypertension: 51 received 1 microg/kg/week of Pegylated-interferon alpha-2b and 51 Pegylated-interferon plus 800 mg/day of ribavirin up to 52 weeks. RESULTS: By intention-to-treat analysis, five patients on monotherapy and eleven on combination therapy achieved a sustained virological response (9.8% vs. 21.6%, p=0.06). The response was more frequent for genotypes 2 or 3 than genotype 1 (66.6% vs. 11.3%, p=0.001). Genotype 1, who had low viral load at start of…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCombination therapyAlpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsPolyethylene GlycolsCirrosi epatica da HCV terapia antivirale.chemistry.chemical_compoundPharmacotherapyInternal medicineHypertension PortalRibavirinmedicineHumansAgedHepatologybusiness.industryRibavirinInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryTreatment OutcomechemistryPortal hypertensionRNA ViralDrug Therapy CombinationbusinessViral load
researchProduct

Rat CNS neurons are not yet programmed to shorten their chromatin repeat length at the end of fetal neurogenesis.

1986

Neurons from rat fetal cerebral hemispheres were grown in a synthetic medium (Maat medium), as previously described, for different periods of time. The repeat length of their chromatin was determined by micrococcal nuclease digestion and compared with that of neurons isolated from postnatal rat brain of corresponding ages. In contrast to the in vivo situation, we found that neurons, dissociated at the 16th gestational day and cultured in vitro, did not undergo the shortening of their chromatin repeat, thus indicating that, at the end of their mitotic cycles, they are not yet programmed to this event. © 1986.

Settore MED/07 - Microbiologia E Microbiologia ClinicaAgingCellular differentiationCentral nervous systemGestational AgeFetusPregnancymedicineAnimalsMitosisCells CulturedCell NucleusNeuronsFetusbiologyNeurogenesisBrainCell DifferentiationdifferentiationCell BiologyDNAneuronChromatinChromatinCell biologyRatsMolecular Weightmedicine.anatomical_structureSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaImmunologybiology.proteinSettore MED/26 - NeurologiaFemaleNeuronMicrococcal nucleaseCell biology international reports
researchProduct

Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients

2021

COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations &gt

0301 basic medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesImmunologyArticleSerologyPersistence (computer science)03 medical and health sciences0302 clinical medicineAntigenDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicineskin and connective tissue diseasesPharmacologyantibody concentrations.biologybusiness.industryImmunogenicitySARS-CoV-2 infectionfungiRantibody concentrationsrespiratory tract diseasesVaccinationbody regions030104 developmental biologyInfectious DiseasesImmunizationImmunologybiology.proteinMedicineAntibodybusinessCOVID-19 vaccineVaccines
researchProduct

Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?

2009

Background/Aim: Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosuppression are potentially at risk of HBV reactivation. In order to assess whether a polymerase chain reaction (PCR) assay for HBV DNA in serum could be used to predict the reactivation of an occult HBV infection, we performed a retrospective study in a cohort of Sicilian patients with oncohaematological diseases. Methods: We studied by a highly sensitive ad hoc nested PCR for serum HBV DNA 75 HBsAg-negative oncohaematological patients requiring chemotherapy. Results: Thirty-three patients (44%) were HBV seronegative (anti-HBc and anti-HBs negative) and 42 patients (56%) were HBV seropositive (a…

MaleHBsAgHepatitis B virusHepatitis C virusAntineoplastic AgentsComorbiditymedicine.disease_causePolymerase Chain ReactionSerologyCohort StudiesBlood serumHepatitis B ChronicPredictive Value of TestsRecurrenceRisk FactorsmedicineHumansSeroconversionRetrospective StudiesHepatitis B virusHepatologybusiness.industryvirus diseasesHepatitis BMiddle Agedmedicine.diseasedigestive system diseasesItalyHematologic NeoplasmsImmunologyDNA ViralFemaleVirus ActivationbusinessNested polymerase chain reactionLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Distribution of VP7 serotypes and VP4 genotypes among rotavirus strains recovered from Italian children with diarrhea

1997

108 rotavirus strains obtained from children with diarrhea hospitalized in Palermo, Italy, in the years 1990-1994, were examined by seminested PCR to study the relative frequency and distribution of the four most common alleles of the gene 4. Such strains were selected from 344 human rotavirus strains recovered in palermo during those years after characterization by electropherotyping, subgrouping and G serotyping. One hundred and seven of the 108 strains could be classified into P types, the P[8], G1 (38.3%) and the P[8], G4 (52.3%) types being predominant. The unique strain whose P genotype could not be identified showed an unusual combination of long migration electrophoretic pattern and…

DiarrheaSerotypemedicine.medical_specialtyGenotypeReoviridaeBiologymedicine.disease_causePolymerase Chain ReactionRotavirus Infectionslaw.inventionCapsidMedical microbiologylawVirologyRotavirusGenotypemedicineHumansUNIQUE VP4SerotypingChildAntigens ViralPolymerase chain reactionMolecular epidemiologyGeneral MedicinePOLYMERASE CHAIN-REACTIONbiology.organism_classificationVirologyGastroenteritisDiarrhearotavirusItalyChild PreschoolRNA ViralCapsid Proteinsmedicine.symptomArchives of Virology
researchProduct

Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization

2022

Abstract Aims Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has had a serious worldwide impact on human health. On December 2020, an immunization campaign with a COVID-19 mRNA vaccine (Comirnaty-BNT162b2 Pfizer-BioNTech) was started in Italy, first targeting healthcare workers (HCWs). This study aims to investigate the antibodies that are response against SARS-CoV-2 vaccine. Methods and Results The kinetics and the persistence of both anti-S1/S2 IgGs and neutralizing antibodies (Nt-Abs) were investigated in 76 HCWs through a 4-month follow-up with multiple testing points starting at the first dose. Temporal analysis of SARS-CoV-2 Abs titre kinetics showed three diff…

Settore MED/07 - Microbiologia E Microbiologia ClinicaVaccines SyntheticCOVID-19 VaccinesSARS-CoV-2VaccinationCOVID-19General Medicineneutralizing antibodies.Settore MED/42 - Igiene Generale E ApplicataAntibodies ViralAntibodies NeutralizingApplied Microbiology and BiotechnologyKineticsItalyhealthcare workerImmunoglobulin GSpike Glycoprotein CoronavirusHumansmRNA Vaccineskinetics of antibodieBNT162 VaccineBiotechnologyJournal of Applied Microbiology
researchProduct

413 Bayesian coalescent inference of hepatitis C virus introduction from molecular sequences: The camporeale model

2006

HepatologyHepatitis C virusBayesian probabilitymedicineInferenceComputational biologyBiologymedicine.disease_causeVirologyCoalescent theoryJournal of Hepatology
researchProduct

IL-10 and TNF-α polymorphisms and the recovery from HCV infection

2003

Hepatitis C virus (HCV) infection becomes chronic in about 85% of infected individuals, whereas only 15% of infected people clear spontaneously the virus. It is conceivable that the host immunogenetic background influences the course of infection in term of recovery. Thus, in this study we have evaluated the effect of functionally relevant polymorphisms at tumor necrosis factor-alpha (TNF-alpha, i.e., 2 biallelic polymorphisms at nt -863 and nt-308 of the promoter) and interleukin-10 (IL-10) loci (i.e., 1 biallelic polymorphism at nt -1082 of the promoter), on the clearance of HCV infection. To this purpose, we compared 18 Sicilian patients who had spontaneously recovered from previous HCV …

AdultMaleGenotypeHepatitis C virusmedicine.medical_treatmentImmunologyInfection groupBiologymedicine.disease_causePolymorphism Single NucleotideViruspolymorphismImmunoenzyme TechniquesGenotypemedicinecytokineImmunology and AllergyHumansIn patientTumor Necrosis Factor-alphaGeneral MedicineHepatitis C ChronicVirologyHepatitis CInterleukin-10Interleukin 10CytokineTNF-αImmunologyHCVIL-10Tumor necrosis factor alphaFemale
researchProduct

Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.

2016

Clearance of hepatitis C virus (HCV) via antiviral treatment changes the course of liver disease. We evaluated the benefit of sustained virologic response (SVR) in patients with HCV and cirrhosis without (stage 1) and with (stage 2) esophageal varices (EV).We performed a prospective cohort study of 444 patients with HCV and compensated cirrhosis (218 with stage 1 and 226 with stage 2 disease) treated with peg-interferon and ribavirin from June 2001 through December 2009 at the University of Palermo, Italy and followed for a median of 7.6 years (range, 1-12.6 years). We used Cox regression analysis to identify variables associated with appearance or progression of EVs, development of hepatoc…

Liver CirrhosisMaleCirrhosisSustained Virologic ResponseHepacivirusEsophaguGastroenterologyPolyethylene GlycolsLiver diseasechemistry.chemical_compound0302 clinical medicineEsophageal varicesProspective StudiesProspective cohort studyHazard ratioGastroenterologyvirus diseasesMiddle AgedPortal PressureHepatitis CRecombinant ProteinsIntention to Treat AnalysisItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemalemedicine.medical_specialtyInterferon alpha-2Lower riskEsophageal and Gastric VaricesAntiviral Agents03 medical and health sciencesInternal medicineHypertension PortalRibavirinmedicineHumansAgedProportional Hazards ModelsHepatologybusiness.industryRibavirinBleedingInterferon-alphaLong-Term Outcomemedicine.diseasedigestive system diseaseschemistrybusinessFollow-Up StudiesGastroenterology
researchProduct

Phylogenetic Analysis of isolates from new cases of HBV infection in Southern Italy.

2012

The level of endemicity of hepatitis B virus (HBV) infections in Italy is low and genotype D infections predominant. New HBV strains may however be introduced as a result of movements of people from regions of high endemicity. The aim of the present study was to determine whether strains from new cases of acute hepatitis B detected in southern Italy were due to endemic or new HBV strains. We studied 34 isolates from patients with acute hepatitis B infection, and 35 from chronic hepatitis B patients. A phylogenetic analysis of preS/S region was done by comparing the sequences from the acute and chronic cases with references sequences. The study showed that 44% of strain from acute hepatitis …

Microbiology (medical)AdultMalemedicine.medical_specialtyHepatitis B virusSettore MED/07 - Microbiologia E Microbiologia ClinicaGenotypeBiologymedicine.disease_causeMicrobiologyLiver diseaseEpidemiologyGenotypeGeneticsmedicineHumansMolecular BiologyEcology Evolution Behavior and SystematicsPhylogenyAgedHepatitis B virusAged 80 and overMolecular EpidemiologySettore MED/12 - GastroenterologiaMolecular epidemiologyPhylogenetic treeSequence Analysis DNAHepatitis BMiddle Agedmedicine.diseaseHepatitis BVirologyInfectious DiseasesItalyImmunologyDNA ViralFemaleViral hepatitisHBV genotypes molecular epidemiology Acute HBV infection phylogenetic analysis
researchProduct

Response-adjusted α-interferon therapy for chronic hepatitis C in HIV-infected patients

2000

Abstract In patients with chronic hepatitis C and HIV infection, responsiveness to the standard schedule of α-interferon (IFN) is unsatisfactory. To quantify the effectiveness of tailoring IFN dosage according to HCV viral load under treatment, we enrolled 41 patients (M/F 32/9) chronically coinfected by HCV and HIV with chronic liver disease. All were former i.v. drug addicts, with a mean age of 32±4 years, and had clinical and histological evidence of chronic hepatitis (10% with cirrhosis). The CDC stage was A1 in five, A2 in 14, A3 in eight, B2 in eight, B3 in three and C3 in three. Twenty four patients were on triple therapy with protease inhibitors, 11 were on two-drug anti-HIV regimen…

AdultMaleMicrobiology (medical)medicine.medical_specialtyCirrhosisSubstance-Related DisordersAlpha interferonHIV InfectionsHepacivirusChronic liver diseaseAntiviral AgentsGastroenterologyLiver diseaseInternal medicinemedicineHumansPharmacology (medical)Interferon alfabusiness.industryHIVInterferon-alphavirus diseasesGeneral MedicineHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseCD4 Lymphocyte CountTreatment OutcomeInfectious DiseasesImmunologyPatient ComplianceFemaleViral diseasebusinessViral loadmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the E…

2022

Background and aim: Direct Acting Antivirals(DAAs) achieve the highest rate of sustained viral re- sponse(SVR) in patients with genotype-1b(G1b) Hepatitis C virus(HCV) infection. Reducing treatment du- ration can simplify the management and improve adherence of therapy. Patients and methods: The study evaluates the efficacy of 8 weeks of elbasvir/grazoprevir regimen in 75 treatment-naïve(TN), G1b patients with mild-moderate fibrosis(Liver Stiffness by Fibroscan®&lt; 9.0 kPa). Viral load(VL) has been evaluated by Roche TaqMan RT-PCR(LLOQ &lt; 15 IU/ml). Results: Mean age was 61.0 ±14.2 years, 44% were male, mean LS by Fibroscan®was 6.1 ±1.8 kPa. Twenty-eight patients(37.3%) had an HOMA &gt; …

CyclopropanesMalemedicine.medical_specialtyElbasvirGenotypeHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyAntiviral AgentsSettore MED/07Insulin resistanceFibrosisInternal medicineQuinoxalinesRibavirinmedicineElbasvir GrazoprevirHumansAgedBenzofuransSulfonamidesHepatologybusiness.industryGastroenterologyImidazolesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseAmidesHepatitis CSustained virological responseRegimenGlucoseGrazoprevirHCVRNADrug Therapy CombinationFemaleCarbamatesSafetyLiver stiffnessbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Detection of enteric adenoviruses 40 and 41 in stool specimens by monoclonal antibody-based enzyme immunoassays

1996

To examine the role of enteric adenoviruses (Ad40 and Ad41) in children with acute gastroenteritis, we evaluated 273 children with diarrhoea and 137 without enteric symptoms in Palermo, Italy, during an 8-month period. Stools were tested by two home-made monoclonal-based ELISAs to detected genus-specific adenovirus antigen and to type Ad40 and Ad41. Twenty-five samples (6.1%) were found to contain adenovirus, 18 of which were grown in Graham 293 and in HEp-2 cells. Ad40 and Ad41 were detected in 2.6% of children with diarrhoea and in none in the control group, while non-enteric adenoviruses were obtained from both patients (3.2%) and controls (6.5%). Samples containing Ad40 and Ad41 were po…

Diarrheamedicine.drug_classImmunologyEnzyme-Linked Immunosorbent AssayMonoclonal antibodymedicine.disease_causeVirusCell LineAdenovirus Infections HumanFecesAgglutination TestsVirologyPrevalencemedicineHumansTypingChildbiologybusiness.industryAdenoviruses HumanAntibodies Monoclonalbiology.organism_classificationVirologyGastroenteritisLatex fixation testAdenoviridaeMastadenovirusDiarrheaItalyEvaluation Studies as TopicMonoclonalmedicine.symptombusinessResearch in Virology
researchProduct

The risk of hepatocellular carcinoma in HBV cirrhosis is affected by polymorphisms of the MERTK gene

2014

MERTK GeneCirrhosisHepatologybusiness.industryHepatocellular carcinomaGastroenterologyCancer researchMedicineHCC HBV MERTK Gene Polymorphismsbusinessmedicine.diseaseDigestive and Liver Disease
researchProduct

Genotyping of Legionella pneumophila serogroup 1 strains isolated in Northern Sicily, Italy.

2008

During a three-year period, from April 2002 to May 2005, one hundred-forty-seven samples, taken from technical systems of water distribution at point of use, were repeatedly collected at six different sites in Northern Sicily and assayed for the presence of Legionella pneumophila serogroup 1 and serogroups 2 to 14. At the first samplings, the water distribution systems of all the sites were heavily contaminated, and disinfection treatments by the superheat and flush method were therefore performed. Treatments were always successful against L. pneumophila sg.1, but only in a few cases against all other serogroups. Eighty-six strains of L. pneumophila sg. 1, isolated from 26 of these samples,…

DNA BacterialDisinfectionMolecular EpidemiologySettore MED/07 - Microbiologia E Microbiologia ClinicaGenotypeCluster AnalysisFresh WaterSequence Analysis DNAAmplified Fragment Length Polymorphism AnalysisLegionella pneumophila Surveillance Water distribution system Molecular typing Amplified fragment length polymorphismSicilyBacterial Typing TechniquesLegionella pneumophila
researchProduct

Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated ampli…

2007

Monitoring of HCV-RNA in blood during antiviral therapy is performed mostly by commercially available reverse transcription polymerase chain reaction-based (RT-PCR) assays, with a lower detection limit of 30-50 IU/mL of HCV-RNA. Use of different tests in the pivotal trials of combination therapy has generated some discordance, in terms of predictive value of the early virological response (EVR). To evaluate whether the use of a more sensitive test, as a qualitative assay based on transcription mediated amplification (TMA) with a lower detection limit of 5-10 IU/mL of HCV-RNA, may obtain a better prediction of EVR and of the ultimate virological outcome, we retrospectively evaluated serial s…

Malemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/09 - Medicina InternaCombination therapyGenotypeTranscription GeneticTranscription-mediated amplificationHepacivirusAlpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsSensitivity and Specificityantiviral therapy EVR HCV chronic hepatitis HCV-RNA RT-PCR TMAPolyethylene Glycolschemistry.chemical_compoundInterferonPredictive Value of TestsVirologyInternal medicineRibavirinmedicineHumansRetrospective StudiesSettore MED/12 - GastroenterologiaHepatologybiologybusiness.industryReverse Transcriptase Polymerase Chain ReactionRibavirinInterferon-alphaNucleic acid amplification techniqueHepatitis C Chronicbiology.organism_classificationVirologydigestive system diseasesRecombinant ProteinsInfectious DiseasesReal-time polymerase chain reactionTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessNucleic Acid Amplification Techniquesmedicine.drug
researchProduct

Phylogenetic reconstruction of HCV genotype 1b dissemination in a small city centre: The Camporeale model

2008

Several seroepidemiological population-based surveys carried out in Italy have shown a high prevalence of hepatitis C virus (HCV) infection. Camporeale (CP), a small Sicilian town with a 10.4% prevalence of HCV mostly genotype 1b, probably represents a specific context, since intravenous drug addiction, and sexual promiscuity are almost absent. In order to reconstruct the pattern of introduction and diffusion of HCV in this ecological niche, the NS5 genomic region of 72 HCV genotype 1 isolates (39 from CP and 33 collected throughout Sicily) was amplified and sequenced. Sequences were aligned and analyzed by BioEdit, PAUP and BEAST, and their molecular evolution compared. Thirty-eight HCV ge…

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaUrban PopulationSequence analysisIatrogenic DiseasePopulationHepacivirusViral Nonstructural Proteinsmolecular epidemiologyMonophylyFlaviviridaecoalescent inference analysiPhylogeneticsVirologyGenotypePrevalenceCluster AnalysisHumanshepatitis C virueducationSicilyPhylogenyAgedGeneticsSettore MED/12 - Gastroenterologiaeducation.field_of_studyMolecular epidemiologybiologyPhylogenetic treeSequence Analysis RNAiatrogenic routeBayes TheoremHepatitis C ChronicMiddle Agedbiology.organism_classificationHepatitis CVirologyInfectious DiseasescommunityFemaleMonte Carlo MethodJournal of Medical Virology
researchProduct

Impact of HBV genotypes A and D genetic variability on infection evolution

2015

HBV is characterized by a high genetic variability, which is the basis of its classification into eight genotypes (A-H). HBV infection is associated with different outcomes, from self-limiting acute hepatitis to active chronic hepatitis, asymptomatic carriage, and occult infection. The aim of this study was to analyze the genetic variability of HBV genotypes A and D isolates from 79 cases of self-limiting acute hepatitis and chronic hepatitis, in order to identify HBV variants associated with resolution or chronicity of acute HBV infection. The entire preS-S sequence and a fragment of 346 bp of the preC-C region, containing Enhancer II and Basal Core Promoter sequences, were analyzed. A phy…

AdultMaleMicrobiology (medical)Hepatitis B virusSettore MED/07 - Microbiologia E Microbiologia ClinicaGenotypeAcute hepatitis BBiologymedicine.disease_causeMicrobiologyLiver diseaseViral ProteinspreC/C mutationGeneticImmune-escape mutationGenetic variationGenotypeGeneticsmedicineHumansViral ProteinGenetic variabilityMolecular BiologyEcology Evolution Behavior and SystematicsPhylogenyAgedHepatitis B virusPolymorphism GeneticpreS/S mutationGenetic VariationHepatitis B viruHepatitis BMiddle Agedmedicine.diseaseHepatitis BVirologyBiological EvolutionEcology Evolution Behavior and SystematicInfectious DiseasesAmino Acid SubstitutionViral evolutionImmunologyMutationFemaleViral hepatitisHuman
researchProduct

Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy

2021

Background: Occurrence of hepatitis C virus (HCV) infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings. Aim: To report the use of phylogenetic analysis in the clinical risk management of an HCV outbreak among 128 thalassaemia outpatients followed at a thalassaemia centre of an Italian hospital. Methods: Epidemiological investigation and root-cause analysis were performed. All patients with acute hepatitis and known chronic infection were tested for HCV RNA, HCV genotyping, and NS3, NS5A, and NS5B HCV genomic region sequencing. To identify transmission clusters, phylogenetic trees were built for each…

SofosbuvirClinical risk management Hepatitis C virus (HCV) Molecular epidemiology Nosocomial outbreak Phylogenetic analysis Antiviral Agents Bayes Theorem Disease Outbreaks Genotype Hepacivirus Humans Italy Phylogeny Risk Management Hepatitis C ThalassemiaHepacivirusHepacivirus030501 epidemiologySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeDisease OutbreaksSettore MED/07chemistry.chemical_compoundSettore BIO/13 - Biologia ApplicataEpidemiologyMedicinePhylogenySettore MED/12 - Gastroenterologia0303 health sciencesClinical risk managementPhylogenetic analysisbiologyTransmission (medicine)virus diseasesGeneral MedicineHepatitis CHepatitis C virus (HCV)Hepatitis CInfectious DiseasesItalyMolecular epidemiologyThalassemia0305 other medical sciencemedicine.drugMicrobiology (medical)Ledipasvirmedicine.medical_specialtyGenotypeHepatitis C virusAntiviral Agents03 medical and health sciencesPhylogenetic analysiInternal medicineHumansRisk Management030306 microbiologybusiness.industryNosocomial outbreakBayes Theorembiology.organism_classificationmedicine.diseasedigestive system diseasesChronic infectionchemistrybusiness
researchProduct

Age and Cytokine Gene Variants Modulate the Immunogenicity and Protective Effect of SARS-CoV-2 mRNA-Based Vaccination

2023

The introduction of anti-SARS-CoV-2 vaccines in late 2020 substantially changed the pandemic picture, inducing effective protection in the population. However, individual variability was observed with different levels of cellular response and neutralizing antibodies. We report data on the impact of age, gender, and 16 single nucleotide polymorphisms (SNPs) of cytokine genes on the anti-SARS-CoV-2 IgG titers measured 31 and 105 days after administration of the second dose of BNT162b2 vaccine to 122 healthy subjects from the health care staff of the Palermo University Hospital, Italy. The higher titers at 31 days were measured in the younger subjects and in subjects bearing T-positive genotyp…

PharmacologyTNFA rs1800629anti-SARS-CoV-2 S1/S2 IgGanti-SARS-CoV-2 vaccineSettore MED/07 - Microbiologia E Microbiologia ClinicaImmunologyanti-SARS-CoV-2 vaccine; anti-SARS-CoV-2 S1/S2 IgG; cytokine gene SNPs; <i>IL-1R1 rs2234650</i>; <i>IL-6 rs1800795</i>; <i>IL-4 rs2243250</i>; <i>TNFA rs1800629</i>IL-1R1 rs2234650Infectious DiseasesIL-4 rs2243250Drug DiscoveryIL-6 rs1800795Settore MED/05 - Patologia ClinicaPharmacology (medical)cytokine gene SNPs.
researchProduct

Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.

2011

Background Genotype 1 (G1) chronic hepatitis C (CHC) patients achieving a rapid virological response (RVR) on pegylated interferon (PEG-IFN) plus ribavirin have a high chance of sustained virological response (SVR), influenced by IL28B status, viral load, fibrosis and insulin resistance. We assessed whether 25-hydroxyvitamin D (25[OH]D) serum levels are linked to RVR and can be used together with IL28B to construct a pretreatment model to predict RVR. Methods A total of 117 consecutive patients with G1 CHC were evaluated by biopsy and anthropometric and metabolic measurements. 25(OH)D serum levels were measured by HPLC. IL28B rs12979860 and rs8099917 polymorphisms were also evaluated. All p…

AdultMaleStandard of careGenotypeHepacivirusAntiviral AgentsPolymorphism Single NucleotidePolyethylene GlycolsVirological responsechemistry.chemical_compoundChronic hepatitisPegylated interferonRisk FactorsGenotypeVitamin D and neurologyMedicineHumansPharmacology (medical)Vitamin DPharmacologybusiness.industryRibavirinInterleukinsInterferon-alphaStandard of CareHepatitis C ChronicMiddle AgedViral LoadRecombinant ProteinsInfectious DiseasesTreatment OutcomechemistryImmunologyFemaleInterferonsbusinessmedicine.drugAntiviral therapy
researchProduct

Triiodothyronine accelerates the synthesis of synapsin I in developing neurons from fetal rat brain cultured in a synthetic medium.

1990

The effect of Triiodothyronine (T3) on Synapsin I appearance in rat cortical neurons has been investigated in vitro. Neuronal cultures from 16-day-old fetal rat brain grown in the absence of T3, express immunohystochemically detectable Synapsin I at the 14th day in vitro. The addition of the hormone to the culture medium determines an early (at the 7th day in vitro) appearance of fluorescent dots specific for Synapsin I. © 1990 Plenum Publishing Corporation.

Synapsin Imedicine.medical_specialtyCNS developmentCentral nervous systemFluorescent Antibody TechniqueNerve Tissue ProteinsBiologySettore BIO/19 - Microbiologia GeneraleBiochemistryCellular and Molecular NeuroscienceFetusInternal medicinemedicineAnimalschemically defined mediumimmunofluorescenceCells CulturedNeuronsFetusTriiodothyronineNeuroscience (all)BrainGeneral MedicineSynapsinsIn vitroCulture MediaRatsChemically defined mediummedicine.anatomical_structureEndocrinologynervous systemneuronal cultureCerebral cortexCell cultureTriiodothyronineSettore MED/26 - NeurologiaSynapsin 1Neurochemical research
researchProduct

HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors

2013

Abstract Due to error-prone RNA polymerase and the lack of proofreading mechanisms, to the spread worldwide and probable long-term presence in human population, HCV showed a high degree of inter- and intra-subtype genetic variability. Protease inhibitors (PIs), a new class of drugs, have been designed specifically on the HCV genotype 1 NS3 protease three-dimensional structure. The viral genetic barrier limits the efficacy of PIs, and fourteen loci in the HCV NS3 gene are involved in resistance to PIs. A sensitive method (15 UI/ml) for study the HCV genetic profile of 125 strains from patients naive to PIs, was developed through the use of new degenerate primers for subtype 1b. We observed t…

MaleMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_treatmentPopulationLocus (genetics)HepacivirusIntra-subtype variabilityViral Nonstructural ProteinsBiologyMicrobiologyHCV genetic barrierNS3 sequencingDrug Resistance ViralGeneticsmedicineHumansGenetic variabilityTransversioneducationMolecular BiologyGenePhylogenyEcology Evolution Behavior and SystematicsAgedGeneticseducation.field_of_studyNS3ProteaseWild typeGenetic Variationvirus diseasesHepatitis C ChronicMiddle AgedProtease inhibitorsVirologyIFN-free therapyInfectious DiseasesMutationFemaleHCV genetic barrier; IFN-free therapy; Intra-subtype variability; NS3 sequencing; Protease inhibitors
researchProduct

Viral Sequence Analysis of Occult HBV Infection and Its Reactivation in Immunosuppressed Patients

2012

Mechanisms associated with reactivation of hepatitis B virus (HBV) in patients with occult HBV infection (OBI) remain unclear. In some cases immunosuppression is an enhancer of viral replication. However, not all patients with OBI who undergo immunosuppression experience reactivation. This study explores the role of viral heterogeneity as a determinant of occult HBV reactivation. HBV genotype, mutation patterns and quasispecies were assessed by sequencing the PreS/S region of 16 patients with OBI undergoing chemotherapy, 3 of whom experienced a OBI reactivation. The latter were also assessed at the time of reactivation. Phylogenetic analysis identified low nucleotide and amino acid diversit…

MaleHepatitis B virusSettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/12 - GastroenterologiaGenotypeoccult HBV HBV reactivation phylogenetic analysismolecular epidemiologyGenetic VariationSequence Analysis DNAHepatitis BImmunocompromised HostDNA ViralHumansFemaleRetrospective Studies
researchProduct

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C

2007

SUMMARY Aims  To assess whether host metabolic factors influence the degree of hepatic steatosis and fibrosis in patients infected with hepatitis C virus, and to evaluate the impact of anti-viral therapy on insulin resistance and serum levels of adipocytokines. Methods  Clinical and biochemical features, anthropometrical characteristics, and levels of fasting insulin, leptin, adiponectin and resistin were measured in ‘naive’ patients with chronic hepatitis C, before, during and after therapy with Peg-Interferon-alpha 2a plus Ribavirin. Results  Forty-eight patients were included (M/F 28/20; mean age 50.0 ± 12.6 years; 62.5% genotype-1). Body mass index was 26.4 ± 4.0 kg/m2, and visceral obe…

medicine.medical_specialtyHepatologyAdiponectinbusiness.industryLeptinInsulinmedicine.medical_treatmentGastroenterologyAdipokinemedicine.diseaseInsulin resistanceEndocrinologyFibrosisInternal medicinemedicinePharmacology (medical)ResistinSteatosisbusinessAlimentary Pharmacology &amp; Therapeutics
researchProduct

Selective culture of rat CNS neurons in a synthetic medium.

1983

A Chemically Defined Medium is described which facilitates the survival of neurons in primary cultures of rat cerebral hemispheres. More than 90% of all cells were identified as neurons using neurofilament as a marker in an immunocytochemical assay. In contrast, serum-supplemented medium, by stimulating nonneuronal cell proliferation, hinders the survival of neurons in culture.

NeuronsNonneuronal cellNeurofilamentGeneral NeuroscienceBrainDermatologyGeneral MedicineBiologyEmbryo MammalianCell biologyCulture MediaRatsPsychiatry and Mental healthChemically defined mediumnervous systemCell cultureAnimalsNeurology (clinical)NeurogliaCells CulturedItalian journal of neurological sciences
researchProduct

HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated…

2003

Abstract Background/Aims HVR-1 quasispecies composition and evolution were investigated in patients chronically infected with genotype 1b HCV, treated with PEG-IFN α2b or STD-IFN α2b plus RBV. Methods HVR-1 heterogeneity was assessed by calculating nucleotidic complexity, diversity, synonymous (S) and non-synonymous (NS) substitutions at baseline, after 4 weeks of therapy ( T 1) and at follow-up ( T 18). Evolution of viral quasispecies was analysed by constructing phylogenetic trees. Results No correlation of baseline viremia with heterogeneity was observed. Nucleotidic complexity was lower in patients showing early virological response, and tended to be inversely correlated to viral load d…

AdultMaleHepacivirusHepatitis C virusViremiaHepacivirusViral quasispeciesInterferon alpha-2medicine.disease_causeAntiviral AgentsVirusPolyethylene GlycolsEvolution MolecularViral Proteinschemistry.chemical_compoundFlaviviridaeDrug Resistance ViralRibavirinmedicineHumansPhylogenyHepatologybiologyRibavirinGenetic VariationInterferon-alphaHepatitis C ChronicMiddle AgedPrognosisbiology.organism_classificationmedicine.diseaseVirologyRecombinant ProteinschemistryImmunologyDrug Therapy CombinationFemaleViral loadHCV Interferon Quasispecies HVR-1
researchProduct

Detection of IgM antibodies specific for measles virus by capture and indirect enzyme immunoassays.

1995

Summary During a measles outbreak, 112 serum specimens from 88 hospitalized patients were received in our laboratory for investigation of a morbilliform rash. These specimens (88 acute- and 24 convalescent-phase) were tested for the presence of measles-specific IgM antibodies by a capture EIA (enzyme immunoassay) using peroxidase-conjugated measles virus antigens and by an indirect EIA. Commercially available indirect EIA kits for measles-specific IgM antibodies were also used and compared with our homemade EIAs. Specificity studies included a collection of serum specimens containing rheumatoid factor, antinuclear antibodies or IgM antibodies specific to other viruses, and sera from blood d…

AdultTime FactorsAnti-nuclear antibodyParamyxoviridaeAdolescentImmunologyEnzyme-Linked Immunosorbent AssayAntibodies ViralMeaslesSensitivity and SpecificitySerologyDisease OutbreaksMeasles virusImmunoenzyme TechniquesMorbillivirusAntibody SpecificityVirologyChlorocebus aethiopsmedicineAnimalsHumansChildVero Cellsbiologymedicine.diagnostic_testInfantbiology.organism_classificationmedicine.diseaseRashVirologyImmunoglobulin MEvaluation Studies as TopicMeasles virusImmunoassayChild PreschoolImmunologyReagent Kits Diagnosticmedicine.symptomCapture EIA IgM Indirect EIAMeaslesResearch in virology
researchProduct

Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients

2021

Background: COVID-19 is a current global threat and characterisation of antibody response to SARS-CoV-2 is vitally important to update vaccine development and strategies. Methods: In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N=272) and subjects vaccinated with BNT162b2 m-RNA Covid-19 vaccine (N=1,256). For each participant socio-demographic data, COVID-19 vaccination records, serological analyses and SARS-CoV-2 infection status have been collected. IgM and IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Findings: Almost all vaccinated subjects (99·8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% vaccinat…

biologybusiness.industryImmunogenicityDiseaseSerologyPersistence (computer science)VaccinationAntigenImmunizationImmunologybiology.proteinMedicineAntibodybusinessSSRN Electronic Journal
researchProduct

Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition.

2020

Therapies for HCV care could change the prevalence and the geographic distribution of genotypes due to differences in Sustained Virologic Response (SVR). In this scenario, uncommon genotypes/subtypes, such as genotype 4, could spread from high-risk groups, replacing genotypes eradicated by antiviral drugs. Genotype eradication is also strongly influenced by the CD8+ T cell response. In this study, the genetic variability in HCV genotype 4 strains obtained from a cohort of 67 patients na&iuml

Settore MED/07 - Microbiologia E Microbiologia ClinicaT-Lymphocyteslcsh:QR1-502Bayesian analysisHepacivirusViral Nonstructural Proteinslcsh:MicrobiologyCoalescent theoryphylodynamicGenotypegenetic variabilityPhylogenyBayesian analysimedia_commonSettore MED/12 - Gastroenterologiavirus diseasesMiddle Agedviral epitopeHepatitis CHost-Pathogen InteractionInfectious Diseasesmedicine.anatomical_structureHost-Pathogen InteractionsHCVtMRCADrugAdultGenotypemedicine.drug_classmedia_common.quotation_subjectT cellmacromolecular substancesHuman leukocyte antigenBiologyAntiviral AgentsArticleYoung AdultT cell recognitionVirologyDrug Resistance ViralmedicineHumansGenetic variabilitygenotype 4AgedDAAAntiviral AgentHepaciviruVirologydigestive system diseasesviral epitopesAntiviral drugCD8RASViruses
researchProduct

ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or Peg-IFN plus ribavirin

2003

The aim of the study was to characterize the interferon sensitivity determining region (ISDR) mutation pattern and its changes at 4 weeks of treatment in a population of patients infected with hepatitis C virus (HCV) genotype 1b receiving standard or PEG-IFN plus ribavirin (RBV), to find possible early correlates of therapy outcome.Forty-five patients with chronic hepatitis due to HCV 1b were treated by PEG-IFN-α2b (n=23) or IFN-α2b (n=22) plus RBV 1000–1200 mg/day. They were classified 24 weeks after stopping therapy as sustained responders (SR), relapsers (REL) or non-responders (NR). Sixteen patients were SR, 12 REL and 17 NR. ISDR mutations were evaluated by direct sequencing at baselin…

Malemedicine.medical_treatmentHepacivirusHepacivirusViral Nonstructural Proteinsmedicine.disease_causePolyethylene GlycolPolyethylene GlycolsCohort Studieschemistry.chemical_compoundInterferonMedicinePharmacology (medical)education.field_of_studybiologyRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomeInfectious DiseasesDrug Therapy CombinationFemaleHumanmedicine.drugGenotypeHepatitis C virusMolecular Sequence DataPopulationInterferon alpha-2Antiviral AgentsVirusFlaviviridaeRibavirinHumansAmino Acid SequenceeducationAntiviral AgentPharmacologyChemotherapyHepacivirubusiness.industryRibavirinInterferon-alphaHepatitis C Chronicbiology.organism_classificationVirologychemistryMutationCohort StudiebusinessSequence Alignment
researchProduct

HCV genotypes in Sicily: is there any evidence of a shift?

2009

The distribution of HCV strains in any area is characterized by a relative prevalence of one genotype, and a number of less prevalent types. In some Western countries a change from the prevalent HCV genotype 1 to genotypes 3 and 4 has been reported in the last decade. In order to assess possible variations of the distribution of HCV genotypes in Sicily, a southern region of Italy, a hospital-based cohort, collected prospectively, of 3,209 subjects with chronic HCV infection was surveyed, comparing the distribution of HCV genotypes during two consecutive periods, from 1997 to 2002 and from 2003 to 2007, according to age and gender. The results show that genotype 1b, which has been historical…

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaAdolescentGenotypeHepatitis C virusHepacivirusmedicine.disease_causeCohort StudiesFlaviviridaeYoung AdultVirologyGenotypemedicinePrevalenceHumansProspective StudiesChildGenotypingSicilyAgedAged 80 and overSettore MED/12 - GastroenterologiaMolecular EpidemiologyMolecular epidemiologybiologybusiness.industryInfantHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationVirologyhepatitis C virusmolecular epidemiology genotypingHCV prevalencechronic hepatitisInfectious DiseasesCohort effectChild PreschoolCohortFemalebusinessJournal of medical virology
researchProduct

Rs4374383 single nucleotide polymorphism of MERTK gene influences the development of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis

2013

MERTK GeneCirrhosisHepatologybusiness.industryHepatocellular carcinomaGastroenterologyCancer researchmedicineSingle-nucleotide polymorphismIn patientmedicine.diseasebusinessDigestive and Liver Disease
researchProduct

Schistosomiasis and antiviral treatment of chronic hepatitis C

2003

AdultHepatologybusiness.industrySchistosomiasisHepatitis C Chronicmedicine.diseaseVirologyChronic hepatitisSplenectomyHumansSchistosomiasisMedicineInterferonsAntiviral treatmentbusinessHepatology
researchProduct

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cir…

2012

Summary.  Genetic factors can influence the outcome of antiviral therapy in chronic hepatitis C (HCV). We evaluated the role of interleukin-28B single nucleotide polymorphisms (SNPs) and inosine triphosphatase (ITPA) gene variants in HCV cirrhosis treated with Peg-Interferon and ribavirin. A prospective cohort of 233 patients with compensated cirrhosis received 1–1.5 μg/kg/week of Peg-Interferon alpha-2b plus 1000–1200 mg/day of RBV for 48 weeks. A sustained virologic response (SVR) was achieved in 27% of patients. On multivariate logistic analysis, the absence of oesophageal varices (OR 3.64 CI 95% 1.27–10.44 P = 0.016), infection with genotype 2 or 3 (OR 4.06, CI 95% 1.08–15.26, P = 0.038…

medicine.medical_specialtyCirrhosisHepatologyCombination therapybusiness.industryRibavirinmedicine.diseaseGastroenterologychemistry.chemical_compoundInfectious DiseaseschemistryVirologyInternal medicineImmunologymedicinePortal hypertensionITPAVaricesRapid Virologic ResponsebusinessProspective cohort studyJournal of Viral Hepatitis
researchProduct

Monkeypox proctitis treated with doxycycline in an HIV MSM returning to Italy from France

2022

No abstract available

MaleAnal painProctitiPublic Health Environmental and Occupational HealthHIV InfectionsMonkeypoxLymphogranuloma venereumAnti-Bacterial AgentsInfectious DiseasesDoxycyclineMonkeypox viruAnti-Bacterial AgentLymphogranuloma Venereum.HumansProctitisHIV InfectionHomosexuality MaleHuman
researchProduct

Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection

2011

Background and aims: Steatosis and insulin resistance (IR) are the major disease modifying in patients with chronic hepatitis C (CHC). Only few studies evaluated these features in patients with chronic hepatitis B (CHB). We aimed to assess the prevalence and the factors related to steatosis and IR in CHB patients, compared with CHC subjects, and to evaluate the potential association between these features and fibrosis severity. Material and methods: One hundred and seventy consecutive patients with CHB (28 HBeAg positive, 142 HBeAg negative), were evaluated using liver biopsy and metabolic measurements and matched for sex, age and body mass index with 170 genotype 1 CHC patients. IR was def…

medicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryDiseasemedicine.diseaseGastroenterologyInsulin resistanceHBeAgFibrosisLiver biopsyInternal medicineBiopsyImmunologymedicineSteatosisbusinessBody mass indexLiver International
researchProduct

Non-invasive assessment of the liver fibrosis by transient elastography (TE) in patients with transfusion-dependent thalassemia

2008

medicine.medical_specialtyHepatologybusiness.industryInternal medicineLiver fibrosisNon invasiveGastroenterologymedicineTransfusion dependent thalassemiaIn patientbusinessTransient elastographyGastroenterologyDigestive and Liver Disease
researchProduct

High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C

2001

Background: Therapy of chronic hepatitis C non- responders to interferon monotherapy with standard doses of interferon plus ribavirin is usually ineffective. Aim: To evaluate the efficacy and tolerability of high-dose prolonged combination retreatment in non- responder patients. Methods: Patients were retreated for 6 months with 6 MU αIFN on alternate days and 1000 or 1200 mg/day ribavirin. HCV-RNA negative patients continued therapy for an additional 6 months. Results: Forty patients (29 males, mean age 49.7 years, 34 genotype 1b, 11 with F3 fibrosis) were treated. At 6 months, 20 (50%) patients were HCV-RNA negative but six of them discontinued therapy because of adverse events. A sustain…

medicine.medical_specialtyChemotherapyHepatologyCombination therapybusiness.industrymedicine.medical_treatmentRibavirinGastroenterologyAlpha interferonGastroenterologySurgerychemistry.chemical_compoundRegimenchemistryTolerabilityInternal medicinemedicinePharmacology (medical)Adverse effectbusinessInterferon alfamedicine.drugAlimentary Pharmacology &amp; Therapeutics
researchProduct

Identification of picobirnavirus from faeces of Italian children suffering from acute diarrhea

1996

Polyacrylamide gel electrophoresis of nucleic acid extracted from stool samples of diarrhoeic children revealed in 3 out of 690 (0.43 %) specimens two electrophoretic bands with a migration pattern characteristic of picobirnavirus ds-RNA. In none of the 92 control children were similar bands detected. No other potential enteric pathogens were found in the patients with picobirnavirus infection.

DiarrheaMaleAcute diarrheaEpidemiologyPicobirnavirusMicrobiologyFecesPicobirnavirus Gastroenteritis PAGEHumansMedicineChildPolyacrylamide gel electrophoresisPicobirnavirusFecesGel electrophoresisbiologybusiness.industryBrief Reportbiology.organism_classificationGastroenteritisPAGEDiarrheaItalyVirus DiseasesRNA ViralElectrophoresis Polyacrylamide GelFemaleViral diseasemedicine.symptombusinessEuropean Journal of Epidemiology
researchProduct

The effect of antiviral therapy on clinical outcome of HCV cirrhosis with portal hypertension: a prospective cohort study.

2006

researchProduct

Infezione occulta da HBV in pazienti con malattie oncoematologiche

2005

researchProduct

EVALUATING THE RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: IS THE SERUM HEPATITIS B PROFILE RELIABLE?

2009

Background/Aim: Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosuppression are potentially at risk of HBV reactivation. In order to assess whether a polymerase chain reaction (PCR) assay for HBV DNA in serum could be used to predict the reactivation of an occult HBV infection, we performed a retrospective study in a cohort of Sicilian patients with oncohaematological diseases. Methods: We studied by a highly sensitive ad hoc nested PCR for serum HBV DNA 75 HBsAg-negative oncohaematological patients requiring chemotherapy. Results: Thirty-three patients (44%) were HBV seronegative (anti-HBc and anti-HBs negative) and 42 patients (56%) were HBV seropositive (a…

nested PCRSettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/12 - GastroenterologiaIMMUNOSUPPRESSIONSettore MED/09 - Medicina InternaHBsAg SEROREVERSIONOBI
researchProduct

A rs4374383 Single Nucleotide Polymorphisms of MERTK gene is linked to a higher likelihood of hepatocellular carcinoma in patients with HCV cirrhosis

2013

MERTK geners4374383 cirrhosisHCC
researchProduct

Epidemiologia molecolare dell'infezione da HCV in un Comune Siciliano

2005

researchProduct

The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study

2007

researchProduct

RIATTIVAZIONE DELL’INFEZIONE OCCULTA DA HBV NEL PAZIENTE IMMUNOCOMPROMESSO: STUDIO DELLA ETEROGENEITÀ VIRALE

2006

researchProduct

Virus-related insulin resistance in HCV genotype 1 chronic hepatitis C : a major disease modifier

2007

researchProduct

VARIABILITY OF THE HBV POL GENE REVERSE-TRANSCRIPTASE DOMAIN IN VIRAL ISOLATES FROM UNTREATED AND LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B PATIENTS

2007

researchProduct

Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.

2012

BACKGROUND: Genotype 1 (G1) chronic hepatitis C (CHC) patients achieving a rapid virological response (RVR) on pegylated interferon (PEG-IFN) plus ribavirin have a high chance of sustained virological response (SVR), influenced by IL28B status, viral load, fibrosis and insulin resistance. We assessed whether 25-hydroxyvitamin D (25[OH]D) serum levels are linked to RVR and can be used together with IL28B to construct a pretreatment model to predict RVR. METHODS: A total of 117 consecutive patients with G1 CHC were evaluated by biopsy and anthropometric and metabolic measurements. 25(OH)D serum levels were measured by HPLC. IL28B rs12979860 and rs8099917 polymorphisms were also evaluated. All…

Vitamin DIL28B chronic hepatitis C
researchProduct

Cinetica della risposta virologica e della comparsa di mutanti virali in pazienti con malattia cronica di fegato HBV-correlatain terapia con adefovir

2005

researchProduct

PEG-INTERFERON PLUS RIBAVIRIN IN COMPENSATED HCV CIRRHOSIS WITH PORTAL HYPERTENSION: THE ROLE OF RAPID AND EARLY VIROLOGICAL RESPONSE IN PREDICTING T…

2009

Settore MED/12 - GastroenterologiaSettore MED/07 - Microbiologia E Microbiologia ClinicaPEG IFN/RBV HCV Cirrhosis SVR EVRHCV PEG-Interferon plus Ribavirin Rapid virological response
researchProduct

HCV genotypes in western Sicily: any evidence for a shift?

2008

Background: The relative prevalence of each HCV strain in a specific country is characterized by a predominant genotype and a number of other sub-prevalent types. Over the last decade a shift away from the prevalent HCV G1 towards G3 and G4 has been reported in some countries, and might affect the global management of HCV disease. Aim: In order to assess any possible variation in the prevalence of HCV genotypes in Sicily, we surveyed an hospital based cohort of subjects with chronic HCV infection observed over the last ten years. Patient and methods: 3209 Italian patients resident in Western Sicily, 1842/1367 M/F, between 1 and 89 years of age, presented at our tertiary referral Laboratory …

Settore MED/12 - GastroenterologiaSettore MED/07 - Microbiologia E Microbiologia Clinicahepatitis C virus molecular epidemiology genotyping HCV prevalencechronic hepatitis
researchProduct

PEG_interferon plus Ribavirin in compensated HCV cirrhosis with portal hypertension: the role of rapid and early virological response in predicting t…

2009

HCV Therapy Rapid virological response
researchProduct

Infezione occulta da HBV in pazienti con malattie linfoproliferative in trattamento chemioterapico

2004

researchProduct

HBsAg quantification in HBeAg negative cirrhosis on nucleoside/nucleotide analogue (NA) and risk of development of HCC

2013

HBsAg-quantification HBeAg-negative cirrhosis therapy
researchProduct

The impact of sustained virological response on clinical outcome in compensated HCV cirrhosis: a prospective cohort study

2007

researchProduct

Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection.

2011

BACKGROUND AND AIMS: Steatosis and insulin resistance (IR) are the major disease modifying in patients with chronic hepatitis C (CHC). Only few studies evaluated these features in patients with chronic hepatitis B (CHB). We aimed to assess the prevalence and the factors related to steatosis and IR in CHB patients, compared with CHC subjects, and to evaluate the potential association between these features and fibrosis severity. MATERIAL AND METHODS: One hundred and seventy consecutive patients with CHB (28 HBeAg positive, 142 HBeAg negative), were evaluated using liver biopsy and metabolic measurements and matched for sex, age and body mass index with 170 genotype 1 CHC patients. IR was def…

Blood GlucoseLiver CirrhosisMaleSettore MED/09 - Medicina InternaBiopsyEnzyme-Linked Immunosorbent AssaySettore MED/08 - Anatomia PatologicaSettore MED/13 - EndocrinologiaBody Mass IndexteatosisHBVPrevalenceHumansInsulinHepatitis B AntibodiesTriglyceridesImmunoassaySettore MED/12 - GastroenterologiaHBV;HCV;steatosisAlanine TransaminaseHepatitis BHepatitis CFatty LiverItalyHCVRegression AnalysisFemaleInsulin ResistanceLiver international : official journal of the International Association for the Study of the Liver
researchProduct

INFEZIONE OCCULTA DA HBV NEL PAZIENTE IMMUNOCOMPROMESSO: STUDIO DELLA ETEROGENEITA’ VIRALE

2007

researchProduct

Bayesian coalescent inference of hepatitis C virus introduction from molecular sequences: the Camporeale model

2006

researchProduct

Riattivazione dell'infezione occulta da HBV nel paziente immunocompromesso:studio dell'eterogeneità virale

2006

researchProduct

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

2007

Aims To assess whether host metabolic factors influence the degree of hepatic steatosis and fibrosis in patients infected with hepatitis C virus, and to evaluate the impact of anti-viral therapy on insulin resistance and serum levels of adipocytokines. Methods Clinical and biochemical features, anthropometrical characteristics, and levels of fasting insulin, leptin, adiponectin and resistin were measured in ‘naı¨ve’ patients with chronic hepatitis C, before, during and after therapy with Peg-Interferon-alpha 2a plus Ribavirin. Results Forty-eightpatientswereincluded(M/F28/20;meanage50.0 12.6years; 62.5% genotype-1). Body mass index was 26.4 4.0 kg/m2 , and visceral obesity was present in 24…

AdultLiver CirrhosisMaleInterferon-alphahcv steatosisHepatitis C ChronicInterferon alpha-2Intra-Abdominal FatMiddle AgedAntiviral AgentsRecombinant ProteinsFatty LiverRibavirinAdipocytesHumansFemaleObesityInsulin ResistanceAlimentary pharmacologytherapeutics
researchProduct

Valutazione della clearance di HCV-RNA sotto trattamentio antivirale con Transcription-Mediated Amplification (TMA)

2005

researchProduct

Infezione occulta da HBV nel paziente immunocompromesso.studio dell'eterogeneità virale

2007

researchProduct

High rate of spontaneous viral clearance in patients with iatrogenic acute hepatitis C

2006

researchProduct